10/26
argenx Announces Positive Top-Line Results from Phase 2 Study of Investigational Celiac Disease Treatment
On October 8th, 2026, argenx announced positive top-line results from the Phase 2 study of FB102, an investigational treatment for celiac disease. The findings suggest that FB102 may help protect…